Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Eltrombopag in Elderly Patients with Chronic Immune Thrombocytopenia: Analysis of Five Clinical Trials,

Harold J. Olney, MD, Ingrid Pabinger, MD, Bhabita Mayer, MSc, Kalpana Bakshi, BS, MS, Christine K Bailey, PhD, Andres Brainsky, MD

Blood (2011) 118 (21): 3294.

https://doi.org/10.1182/blood.V118.21.3294.3294

Published: 2011

Journal Articles

EXTEND Study Update: Safety and Efficacy of Eltrombopag In Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2010

Mansoor N. Saleh, MD, Gregory Cheng, MD, PhD, James B. Bussel, MD, Huiping Sun, Bhabita Mayer, MSc, Christine Bailey, PhD, Andres Brainsky, MD

Blood (2010) 116 (21): 67.

https://doi.org/10.1182/blood.V116.21.67.67

Published: 2010

Journal Articles

Incidence of Thromboembolic Events Across Eltrombopag Clinical Trials In Chronic Immune Thrombocytopenia (ITP)

James B. Bussel, MD, Gregory Cheng, MD, PhD, Mansoor N. Saleh, MD, Bhabita Mayer, MSc, Sandra Y. Vasey, MS, Andres Brainsky, MD

Blood (2010) 116 (21): 70.

https://doi.org/10.1182/blood.V116.21.70.70

Published: 2010

Journal Articles

Hemostatic Challenges In Patients Treated with Eltrombopag

Michael D. Tarantino, MD, Patrick F. Fogarty, MD, Bhabita Mayer, MSc, Sandra Y. Vasey, MS, Andres Brainsky, MD

Blood (2010) 116 (21): 2511.

https://doi.org/10.1182/blood.V116.21.2511.2511

Published: 2010

Journal Articles

Efficacy of Eltrombopag In Splenectomized Versus Nonsplenectomized Patients with Chronic ITP In the RAISE Study

Harold J. Olney, MD, CM, FRCP (C), Patrick F. Fogarty, MD, Michael D. Tarantino, MD, Bhabita Mayer, MSc, Sandra Y. Vasey, MS, Andres Brainsky, MD

Blood (2010) 116 (21): 2512.

https://doi.org/10.1182/blood.V116.21.2512.2512

Published: 2010

Journal Articles

Long-Term Treatment of Chronic Immune Thrombocytopenic Purpura with Oral Eltrombopag: Results From the EXTEND Study.

Mansoor N. Saleh, MD, James B. Bussel, MD, Gregory Cheng, Balkis Meddeb, Bhabita Mayer, Christine Bailey, Manuel Aivado

Blood (2009) 114 (22): 682.

https://doi.org/10.1182/blood.V114.22.682.682

Published: 2009

Journal Articles

Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE)

Gregory Cheng, Mansoor N Saleh, James B Bussel, Claus Marcher, Sandra Vasey, Bhabita Mayer, Manuel Aivado, Michael Arning, Nicole L. Stone

Blood (2008) 112 (11): 400.

https://doi.org/10.1182/blood.V112.11.400.400

Published: 2008

Journal Articles

Efficacy and Safety of Repeated Intermittent Treatment with Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic Purpura.

James B Bussel, Bethan Psaila, Mansoor N Saleh, Sandra Vasey, Bhabita Mayer, Nicole L Stone, Michael Arning

Blood (2008) 112 (11): 3431.

https://doi.org/10.1182/blood.V112.11.3431.3431

Published: 2008

Journal Articles

Long-Term Safety and Efficacy of Oral Eltrombopag for the Treatment of Subjects with Idiopathic Thrombocytopenic Purpura (ITP): Preliminary Data from the EXTEND Study.

James B. Bussel, MD, Gregory Cheng, MD, Lidia Kovaleva, MD, Mansoor N. Saleh, MD, Balkis Meddeb, MD, Bhabita Mayer, PhD, J. Lee Fraser, PhD, Manuel Aivado, MD

Blood (2007) 110 (11): 566.

https://doi.org/10.1182/blood.V110.11.566.566

Published: 2007

Journal Articles

Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor.

James B. Bussel, MD, Gregory Cheng, MD, Mansoor Saleh, MD, Lidia Kovaleva, MD, Nicole Stone, PhD, Bhabita Mayer, MS, Julian Jenkins, MS, Andrew Provan, BSc, MBChB, MD

Blood (2006) 108 (11): 475.

https://doi.org/10.1182/blood.V108.11.475.475

Published: 2006

NARROW

Efficacy and Safety of Eltrombopag in Elderly Patients with Chronic Immune Thrombocytopenia: Analysis of Five Clinical Trials,

EXTEND Study Update: Safety and Efficacy of Eltrombopag In Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2010

Incidence of Thromboembolic Events Across Eltrombopag Clinical Trials In Chronic Immune Thrombocytopenia (ITP)

Hemostatic Challenges In Patients Treated with Eltrombopag

Efficacy of Eltrombopag In Splenectomized Versus Nonsplenectomized Patients with Chronic ITP In the RAISE Study

Long-Term Treatment of Chronic Immune Thrombocytopenic Purpura with Oral Eltrombopag: Results From the EXTEND Study.

Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE)

Efficacy and Safety of Repeated Intermittent Treatment with Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic Purpura.

Long-Term Safety and Efficacy of Oral Eltrombopag for the Treatment of Subjects with Idiopathic Thrombocytopenic Purpura (ITP): Preliminary Data from the EXTEND Study.

Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only